Reversing aging in human blood stem cells
Official title: Pharmacological rejuvenation of human hematopoietic stem cells
Funded at Mogling Bio INC · NIH-10811003 · Data updated 2026-11-12
This study is looking at a new drug called CASIN that might help older adults by making their blood-producing stem cells work better again, which could improve issues like anemia and a weaker immune system.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Mogling Bio INC NIH-funded |
| Lab location | 1 site (Cincinnati, United States) |
| Project start | September 23, 2024 |
| Project end | August 31, 2025 |
| Funding year | 2024 |
| Award (this year) | $299,781 |
| NIH project number | 1R43HL172285-01 |
| Project ID | NIH-10811003 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are older adults experiencing age-related blood disorders, such as anemia or weakened immune systems.
✕Less likely to help
Patients who are younger or do not have age-related blood disorders may not benefit from this research.
What this research studies
This research aims to develop a new treatment that can rejuvenate aging human hematopoietic stem cells (HSCs), which are crucial for producing blood cells. The approach focuses on a specific drug, CASIN, that targets a protein called Cdc42, known to be involved in the aging process of these stem cells. By restoring the function of these cells, the research hopes to improve conditions like anemia and weakened immune responses in older adults. The studies will test the effectiveness of CASIN in rejuvenating HSCs outside the body before considering clinical applications.
Why it matters
Potential benefit: If successful, this research could lead to improved blood cell production and immune function in older adults, potentially alleviating age-related anemia and other blood disorders.
How similar studies have gone: Previous studies in animal models have shown promising results in rejuvenating aged stem cells using similar approaches, indicating potential for success in human applications.
Where this research is happening
-
Mogling Bio INC
Cincinnati, United States Active
Researchers
- Principal investigator: Mulloy, James C — Mogling Bio INC
- Study coordinator: Mulloy, James C
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.